Transperineal biopsies of MRI-detected aggressive index lesions in low- and intermediate-risk prostate cancer patients: Implications for treatment decision

详细信息    查看全文

• 作者：A. Gomez-Iturriaga¹ ; ^{agomeziturriaga@gmail.com} ; F. Casquero¹ ; J.I. Lopez² ; A. Urresola³ ; A. Ezquerro³ ; D. Buscher¹ ; P. Bilbao¹ ; J. Crook⁴
• 关键词：Prostate cancer ; Dominant intraprostatic lesion ; Transperineal biopsy ; Multiparametric MRI
• 刊名：Brachytherapy
• 出版年：2017
• 出版时间：January-February 2017
• 年：2017
• 卷：16
• 期：1
• 页码：201-206
• 全文大小：364 K
• 卷排序：16

文摘

Multiparametric MRI (mpMRI) has a potential role for the identification of aggressive cancer that can be targeted for biopsy. We report the incidence and severity of discordant information between the pathology found on the transrectal ultrasound (TRUS)–guided biopsy and the mpMRI findings in patients with favorable or intermediate-risk prostate cancer referred for brachytherapy.Methods and MaterialsFrom March 2014 to September 2015, 10/44 consecutive patients with low- or intermediate-risk prostate cancer referred for brachytherapy presented an aggressive lesion on mpMRI and underwent an MRI-TRUS fusion-guided transperineal biopsy of the index lesion.ResultsA median of two intraprostatic lesions were detected by mpMRI for each patient. Three patients had bilateral disease, and seven had unilateral disease on mpMRI. The median number of cores obtained by MRI-TRUS–guided fusion of the index lesion was 3 (range 2–4). As a result of the re-evaluation consequent to additional information becoming available after the transperineal biopsy, upgrading of Gleason score occurred in 8 of the 10 patients, which changed the risk group in 9 patients. These changes resulted in modification of the proposed treatment in 8 patients.ConclusionsMpMRI-US fusion-targeted biopsy sampling allows detection and characterization of otherwise undetected aggressive disease, often placing men in higher risk groups and altering the treatment approach.